Christoph Johannes Schlimp1, Janne Cadamuro2, Cristina Solomon1, Heinz Redl1, Herbert Schöchl3. 1. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austrian Workers' Compensation Board (AUVA) Research Centre, Vienna, Austria. 2. Department of Laboratory Medicine, University Hospital of Salzburg, Salzburg, Austria. 3. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austrian Workers' Compensation Board (AUVA) Research Centre, Vienna, Austria Department of Anaesthesiology and Intensive Care, Austrian Workers' Compensation Board (AUVA) Trauma Hospital Salzburg, Salzburg, Austria.
Abstract
BACKGROUND: Fluid replacement results in dilutional coagulopathy. We investigated the potential role of fibrinogen, factor XIII and a combination of both to reverse dilutional coagulopathy, assessed by thromboelastometry (ROTEM(®)). MATERIAL AND METHODS: Blood samples from healthy volunteers were analysed undiluted and after 33% dilution in vitro with albumin, gelatine, 130/0.4 hydroxyethyl starch or saline. Diluted samples were incubated with fibrinogen (3 g/70 kg bodyweight equivalent), factor XIII (10,000 IU/70 kg bodyweight equivalent), or a combination of both. Measurements were performed using an extrinsic activated assay (EXTEM(®)) and a functional fibrin polymerisation test (FIBTEM(®)). RESULTS: Compared with baseline, EXTEM clotting time increased with hydroxyethyl starch, exceeding the upper limit of the reference value. Albumin prolonged clotting time within normal limits. Gelatine did not change clotting time, and saline reduced clotting time. Clot formation time increased in colloids only. Maximum clot firmness of both EXTEM and FIBTEM decreased with all fluids, but was less pronounced in saline. Incubation with fibrinogen had no effect on EXTEM maximum clot firmness but improved FIBTEM maximum clot firmness in saline (P <0.001) and albumin (P <0.05), but not gelatine and hydroxyethyl starch). Factor XIII had no effect on any EXTEM and FIBTEM maximum clot firmness results. Fibrinogen and factor XIII combined did not improve EXTEM maximum clot firmness. Fibrinogen and factor XIII did not change FIBTEM maximum clot firmness in hydroxyethyl starch but improved FIBTEM maximum clot firmness in albumin (P <0.001), gelatine (P <0.01) and saline (P <0.001). DISCUSSION: ROTEM parameters in dilutional coagulopathy in vitro cannot be improved with factor XIII alone in any tested diluent. The combination of fibrinogen and factor XIII is highly effective in raising FIBTEM maximum clot firmness after dilution with albumin, gelatine and saline back to normal values, but is ineffective in 130/0.4 hydroxyethyl starch.
BACKGROUND: Fluid replacement results in dilutional coagulopathy. We investigated the potential role of fibrinogen, factor XIII and a combination of both to reverse dilutional coagulopathy, assessed by thromboelastometry (ROTEM(®)). MATERIAL AND METHODS: Blood samples from healthy volunteers were analysed undiluted and after 33% dilution in vitro with albumin, gelatine, 130/0.4 hydroxyethyl starch or saline. Diluted samples were incubated with fibrinogen (3 g/70 kg bodyweight equivalent), factor XIII (10,000 IU/70 kg bodyweight equivalent), or a combination of both. Measurements were performed using an extrinsic activated assay (EXTEM(®)) and a functional fibrin polymerisation test (FIBTEM(®)). RESULTS: Compared with baseline, EXTEM clotting time increased with hydroxyethyl starch, exceeding the upper limit of the reference value. Albumin prolonged clotting time within normal limits. Gelatine did not change clotting time, and saline reduced clotting time. Clot formation time increased in colloids only. Maximum clot firmness of both EXTEM and FIBTEM decreased with all fluids, but was less pronounced in saline. Incubation with fibrinogen had no effect on EXTEM maximum clot firmness but improved FIBTEM maximum clot firmness in saline (P <0.001) and albumin (P <0.05), but not gelatine and hydroxyethyl starch). Factor XIII had no effect on any EXTEM and FIBTEM maximum clot firmness results. Fibrinogen and factor XIII combined did not improve EXTEM maximum clot firmness. Fibrinogen and factor XIII did not change FIBTEM maximum clot firmness in hydroxyethyl starch but improved FIBTEM maximum clot firmness in albumin (P <0.001), gelatine (P <0.01) and saline (P <0.001). DISCUSSION: ROTEM parameters in dilutional coagulopathy in vitro cannot be improved with factor XIII alone in any tested diluent. The combination of fibrinogen and factor XIII is highly effective in raising FIBTEM maximum clot firmness after dilution with albumin, gelatine and saline back to normal values, but is ineffective in 130/0.4 hydroxyethyl starch.
Authors: Dietmar Fries; Werner Streif; Josef Margreiter; Anton Klingler; Gabriele Kühbacher; Wolfgang Schobersberger; Barbara Wirleitner; Petra Innerhofer Journal: Blood Coagul Fibrinolysis Date: 2004-04 Impact factor: 1.276
Authors: Herbert Schöchl; Marc Maegele; Cristina Solomon; Klaus Görlinger; Wolfgang Voelckel Journal: Scand J Trauma Resusc Emerg Med Date: 2012-02-24 Impact factor: 2.953
Authors: Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn Journal: Crit Care Date: 2016-04-12 Impact factor: 9.097
Authors: Thomas Palmaers; Elke Krämer; Julia Hinsenkamp; Hendrik Eismann; Dirk Scheinichen; Paul Frank Journal: Turk J Anaesthesiol Reanim Date: 2019-02-19
Authors: Philipp Groene; Tobias Wiederkehr; Tobias Kammerer; Patrick Möhnle; Melanie Maerte; Andreas Bayer; Klaus Görlinger; Markus Rehm; Simon T Schäfer Journal: Transfus Med Hemother Date: 2019-08-16 Impact factor: 3.747
Authors: Christoph J Schlimp; Wolfgang Voelckel; Kenji Inaba; Marc Maegele; Herbert Schöchl Journal: Scand J Trauma Resusc Emerg Med Date: 2013-10-08 Impact factor: 2.953